866-997-4948(US-Canada Toll Free)

Hepatitis B - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 353 Pages

Hepatitis B - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H1 2017, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 8, 27, 26, 4, 56, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Hepatitis B - Overview 7
Hepatitis B - Therapeutics Development 8
Hepatitis B - Therapeutics Assessment 27
Hepatitis B - Companies Involved in Therapeutics Development 37
Hepatitis B - Drug Profiles 79
Hepatitis B - Dormant Projects 317
Hepatitis B - Discontinued Products 324
Hepatitis B - Product Development Milestones 325
Appendix 334

List of Tables
Number of Products under Development for Hepatitis B, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hepatitis B - Pipeline by Abivax SA, H1 2017
Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H1 2017
Hepatitis B - Pipeline by AIMM Therapeutics BV, H1 2017
Hepatitis B - Pipeline by Akshaya Bio Inc, H1 2017
Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by Altimmune Inc, H1 2017
Hepatitis B - Pipeline by Altravax Inc, H1 2017
Hepatitis B - Pipeline by Amarna Therapeutics BV, H1 2017
Hepatitis B - Pipeline by Arbutus Biopharma Corp, H1 2017
Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H1 2017
Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by Assembly Biosciences Inc, H1 2017
Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Hepatitis B - Pipeline by Benitec Biopharma Ltd, H1 2017
Hepatitis B - Pipeline by Biological E Ltd, H1 2017
Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by Bolder Biotechnology Inc, H1 2017
Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H1 2017
Hepatitis B - Pipeline by Bukwang Pharm Co Ltd, H1 2017
Hepatitis B - Pipeline by CaroGen Corp, H1 2017
Hepatitis B - Pipeline by Celltrion Inc, H1 2017
Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Hepatitis B - Pipeline by Chromis Therapeutics Inc, H1 2017
Hepatitis B - Pipeline by Cocrystal Pharma Inc, H1 2017
Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by CyTuVax BV, H1 2017
Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Hepatitis B - Pipeline by Dynavax Technologies Corp, H1 2017
Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H1 2017
Hepatitis B - Pipeline by Enyo Pharma SA, H1 2017
Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H1 2017
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Hepatitis B - Pipeline by GeneCure LLC, H1 2017
Hepatitis B - Pipeline by GeoVax Labs Inc, H1 2017
Hepatitis B - Pipeline by Gilead Sciences Inc, H1 2017
Hepatitis B - Pipeline by GlaxoSmithKline Plc, H1 2017
Hepatitis B - Pipeline by Green Cross Corp, H1 2017
Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Hepatitis B - Pipeline by Humabs BioMed SA, H1 2017
Hepatitis B - Pipeline by Huons Co Ltd, H1 2017
Hepatitis B - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
Hepatitis B - Pipeline by Immunotope Inc, H1 2017
Hepatitis B - Pipeline by Indian Immunologicals Ltd, H1 2017
Hepatitis B - Pipeline by Intellia Therapeutics Inc, H1 2017
Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H1 2017
Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
Hepatitis B - Pipeline by Johnson & Johnson, H1 2017
Hepatitis B - Pipeline by Kineta Inc, H1 2017
Hepatitis B - Pipeline by Leukocare AG, H1 2017
Hepatitis B - Pipeline by LG Chem, Ltd., H1 2017
Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by Medivir AB, H1 2017
Hepatitis B - Pipeline by Mucosis BV, H1 2017
Hepatitis B - Pipeline by MultiCell Technologies Inc, H1 2017
Hepatitis B - Pipeline by Oncolys BioPharma Inc, H1 2017
Hepatitis B - Pipeline by Panacea Biotec Ltd, H1 2017
Hepatitis B - Pipeline by Pfenex Inc, H1 2017
Hepatitis B - Pipeline by PharmaEssentia Corp, H1 2017
Hepatitis B - Pipeline by Profarma, H1 2017
Hepatitis B - Pipeline by Profectus BioSciences Inc, H1 2017
Hepatitis B - Pipeline by Replicor Inc, H1 2017
Hepatitis B - Pipeline by Rodos BioTarget GmbH, H1 2017
Hepatitis B - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
Hepatitis B - Pipeline by Sanofi, H1 2017
Hepatitis B - Pipeline by Sanofi Pasteur SA, H1 2017
Hepatitis B - Pipeline by Scynexis Inc, H1 2017
Hepatitis B - Pipeline by Shantha Biotechnics Ltd, H1 2017
Hepatitis B - Pipeline by Sinovac Biotech Ltd, H1 2017
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
Hepatitis B - Pipeline by TCM Biotech International Corp, H1 2017
Hepatitis B - Pipeline by Theravectys SA, H1 2017
Hepatitis B - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017
Hepatitis B - Pipeline by Tomegavax Inc, H1 2017
Hepatitis B - Pipeline by Transgene SA, H1 2017
Hepatitis B - Pipeline by Vaxine Pty Ltd, H1 2017
Hepatitis B - Pipeline by VBI Vaccines Inc, H1 2017
Hepatitis B - Pipeline by Vical Inc, H1 2017
Hepatitis B - Pipeline by ViroStatics srl, H1 2017
patitis B - Pipeline by VLP Biotech Inc, H1 2017
Hepatitis B - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Hepatitis B - Dormant Projects, H1 2017
Hepatitis B - Dormant Projects, H1 2017 (Contd..1), H1 2017
Hepatitis B - Dormant Projects, H1 2017 (Contd..2), H1 2017
Hepatitis B - Dormant Projects, H1 2017 (Contd..3), H1 2017
Hepatitis B - Dormant Projects, H1 2017 (Contd..4), H1 2017
Hepatitis B - Dormant Projects, H1 2017 (Contd..5), H1 2017
Hepatitis B - Dormant Projects, H1 2017 (Contd..6), H1 2017
Hepatitis B - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Hepatitis B, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *